Richard Drake, PhD profile page

Richard Drake is a Professor in the Department of Pharmacology and Immunology at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. His lab developed the workflows for glycan-targeted mass spectrometry imaging of clinical tissues and biofluids for biomarker discovery and development of new diagnostics. He is a founder of GlycoPath Inc., recently sold to Bruker Corporation, which developed the GlycoTyper antibody array assay platform for rapid clinical analysis of serum and immune cell glycoproteins. Current efforts are in the large scale application of N-glycan MS imaging methods to identify glycan biomarker panels associated with tumor, stroma and immune regions of cancer tissues. Further, these glycan maps are being used to identify the localized glycoprotein carriers using new sialic acid targeted affinity reagents. The glycan imaging workflows are highly synergistic with emerging multi-modality spatial-omic analysis strategies at the macro and single cell levels.